A new study has found that people living with moderate-to-severe plaque psoriasis continued to experience skin clearance after three years of ongoing treatment with Sun Pharma's Ilumya (tildrakizumab-asmn).

The new data from Sun Pharma is based on the Phase III reSURFACE 1 and reSURFACE 2 studies, which found that at week 64, up to 92% of patients receiving the drug achieved 75% skin clearance, while 35% achieved total skin clearance.

At week 160, as many as 89% still had 75% skin clearance and 16% had totally clear skin.

"It's very encouraging to see these effective response rates with Ilumya over a three-year period, because as clinicians we're often faced with the challenge of finding the right treatment that addresses the chronic nature of plaque psoriasis. We're also starting to learn more about which patients Ilumya may be a fit for," said Dr. Andrew Blauvelt, board-certified dermatologist and president of Oregon Medical Research Centre.

He continued, “In a one-year analysis we saw that Ilumya showed similar results of skin clearance in both patients who were new to biologic therapy and those who had previously been treated with another biologic. Furthermore, with its HCP administration model Ilumya supports treatment adherence and may be a good treatment option for patients who are starting their first biologic treatment or those who have failed previous therapy.”

The data results also demonstrated that Ilumya is among the most cost-effective options compared to other biologic options including secukinumab, guselkumab, ixekizumab, adalimumab, ustekinumab, and etanercept, the firm noted.